Pacira BioSciences (PCRX) Change in Accured Expenses (2010 - 2026)

Pacira BioSciences' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at $3.3 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 30.07% year-over-year to $3.3 million in Q1 2026; TTM through Mar 2026 was $5.4 million, a 65.28% decrease from a year earlier, with the FY2025 full-year figure at $6.9 million, down 52.52% from the prior year.
• Change in Accured Expenses climbed to $3.3 million in Q1 2026 per PCRX's latest filing, from $1.8 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $15.6 million in Q4 2024 and bottomed at -$24.0 million in Q3 2022.
• The 5-year median for Change in Accured Expenses is $421000.0 (2023), against an average of -$993352.9.
• Biggest YoY gain for Change in Accured Expenses was 8630.97% in 2022; the steepest drop was 2273.51% in 2022.
• Year by year, Change in Accured Expenses stood at $3.7 million in 2022, then tumbled by 684.53% to -$21.6 million in 2023, then surged by 172.21% to $15.6 million in 2024, then sank by 88.65% to $1.8 million in 2025, then jumped by 85.34% to $3.3 million in 2026.
• Per Business Quant, the three latest PCRX Change in Accured Expenses figures stand at $3.3 million (Q1 2026), $1.8 million (Q4 2025), and -$5.8 million (Q3 2025).